ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Recombinant Antihemophilic Globulin Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-34M15028
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Recombinant Antihemophilic Globulin Market Research Report 2023
BUY CHAPTERS

Global Recombinant Antihemophilic Globulin Market Research Report 2025

Code: QYRE-Auto-34M15028
Report
June 2025
Pages:96
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Shire (Baxter)
Bayer HealthCare
CSL Limited
Pfizer Inc
Grifols S A
Biogen
Octapharma AG
Novo Nordisk
Greencross
Kedrion S p A
BPL
Hualan Bio
RAAS
Baxalta

Recombinant Antihemophilic Globulin Market

The global market for Recombinant Antihemophilic Globulin was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The recombinant antihemophilic globulin is a drug synthesized by gene recombination technology, which is used to treat patients with hemophilia A. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of clotting factor VIII.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following steps: gene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Recombinant Antihemophilic Globulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Antihemophilic Globulin.
The Recombinant Antihemophilic Globulin market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Recombinant Antihemophilic Globulin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Antihemophilic Globulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Recombinant Antihemophilic Globulin Market Report

Report Metric Details
Report Name Recombinant Antihemophilic Globulin Market
Segment by Type
  • Baikoc
  • Afstyla
  • Altuviiio
Segment by Application
  • Clinical Treatment
  • Drug Research
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Shire (Baxter), Bayer Healthcare, CSL, Pfizer, Grifols, Biogen, Octapharma, Novo Nordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Baxalta
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Recombinant Antihemophilic Globulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Recombinant Antihemophilic Globulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Recombinant Antihemophilic Globulin Market report?

Ans: The main players in the Recombinant Antihemophilic Globulin Market are Shire (Baxter), Bayer Healthcare, CSL, Pfizer, Grifols, Biogen, Octapharma, Novo Nordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Baxalta

What are the Application segmentation covered in the Recombinant Antihemophilic Globulin Market report?

Ans: The Applications covered in the Recombinant Antihemophilic Globulin Market report are Clinical Treatment, Drug Research, Others

What are the Type segmentation covered in the Recombinant Antihemophilic Globulin Market report?

Ans: The Types covered in the Recombinant Antihemophilic Globulin Market report are Baikoc, Afstyla, Altuviiio

Recommended Reports

Recombinant Proteins

Coagulation Factors

Blood Disorder Therapy

1 Recombinant Antihemophilic Globulin Market Overview
1.1 Product Definition
1.2 Recombinant Antihemophilic Globulin by Type
1.2.1 Global Recombinant Antihemophilic Globulin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Baikoc
1.2.3 Afstyla
1.2.4 Altuviiio
1.3 Recombinant Antihemophilic Globulin by Application
1.3.1 Global Recombinant Antihemophilic Globulin Market Value by Application (2024 VS 2031)
1.3.2 Clinical Treatment
1.3.3 Drug Research
1.3.4 Others
1.4 Global Recombinant Antihemophilic Globulin Market Size Estimates and Forecasts
1.4.1 Global Recombinant Antihemophilic Globulin Revenue 2020-2031
1.4.2 Global Recombinant Antihemophilic Globulin Sales 2020-2031
1.4.3 Global Recombinant Antihemophilic Globulin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Recombinant Antihemophilic Globulin Market Competition by Manufacturers
2.1 Global Recombinant Antihemophilic Globulin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Recombinant Antihemophilic Globulin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Recombinant Antihemophilic Globulin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Recombinant Antihemophilic Globulin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Recombinant Antihemophilic Globulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Recombinant Antihemophilic Globulin, Product Type & Application
2.7 Global Key Manufacturers of Recombinant Antihemophilic Globulin, Date of Enter into This Industry
2.8 Global Recombinant Antihemophilic Globulin Market Competitive Situation and Trends
2.8.1 Global Recombinant Antihemophilic Globulin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Recombinant Antihemophilic Globulin Players Market Share by Revenue
2.8.3 Global Recombinant Antihemophilic Globulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Recombinant Antihemophilic Globulin Market Scenario by Region
3.1 Global Recombinant Antihemophilic Globulin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Recombinant Antihemophilic Globulin Sales by Region: 2020-2031
3.2.1 Global Recombinant Antihemophilic Globulin Sales by Region: 2020-2025
3.2.2 Global Recombinant Antihemophilic Globulin Sales by Region: 2026-2031
3.3 Global Recombinant Antihemophilic Globulin Revenue by Region: 2020-2031
3.3.1 Global Recombinant Antihemophilic Globulin Revenue by Region: 2020-2025
3.3.2 Global Recombinant Antihemophilic Globulin Revenue by Region: 2026-2031
3.4 North America Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.4.1 North America Recombinant Antihemophilic Globulin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Recombinant Antihemophilic Globulin Sales by Country (2020-2031)
3.4.3 North America Recombinant Antihemophilic Globulin Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.5.1 Europe Recombinant Antihemophilic Globulin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Recombinant Antihemophilic Globulin Sales by Country (2020-2031)
3.5.3 Europe Recombinant Antihemophilic Globulin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Recombinant Antihemophilic Globulin Market Facts & Figures by Region
3.6.1 Asia Pacific Recombinant Antihemophilic Globulin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Recombinant Antihemophilic Globulin Sales by Region (2020-2031)
3.6.3 Asia Pacific Recombinant Antihemophilic Globulin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.7.1 Latin America Recombinant Antihemophilic Globulin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Recombinant Antihemophilic Globulin Sales by Country (2020-2031)
3.7.3 Latin America Recombinant Antihemophilic Globulin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Recombinant Antihemophilic Globulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Recombinant Antihemophilic Globulin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Recombinant Antihemophilic Globulin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Recombinant Antihemophilic Globulin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Recombinant Antihemophilic Globulin Sales by Type (2020-2031)
4.1.1 Global Recombinant Antihemophilic Globulin Sales by Type (2020-2025)
4.1.2 Global Recombinant Antihemophilic Globulin Sales by Type (2026-2031)
4.1.3 Global Recombinant Antihemophilic Globulin Sales Market Share by Type (2020-2031)
4.2 Global Recombinant Antihemophilic Globulin Revenue by Type (2020-2031)
4.2.1 Global Recombinant Antihemophilic Globulin Revenue by Type (2020-2025)
4.2.2 Global Recombinant Antihemophilic Globulin Revenue by Type (2026-2031)
4.2.3 Global Recombinant Antihemophilic Globulin Revenue Market Share by Type (2020-2031)
4.3 Global Recombinant Antihemophilic Globulin Price by Type (2020-2031)
5 Segment by Application
5.1 Global Recombinant Antihemophilic Globulin Sales by Application (2020-2031)
5.1.1 Global Recombinant Antihemophilic Globulin Sales by Application (2020-2025)
5.1.2 Global Recombinant Antihemophilic Globulin Sales by Application (2026-2031)
5.1.3 Global Recombinant Antihemophilic Globulin Sales Market Share by Application (2020-2031)
5.2 Global Recombinant Antihemophilic Globulin Revenue by Application (2020-2031)
5.2.1 Global Recombinant Antihemophilic Globulin Revenue by Application (2020-2025)
5.2.2 Global Recombinant Antihemophilic Globulin Revenue by Application (2026-2031)
5.2.3 Global Recombinant Antihemophilic Globulin Revenue Market Share by Application (2020-2031)
5.3 Global Recombinant Antihemophilic Globulin Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Shire (Baxter)
6.1.1 Shire (Baxter) Company Information
6.1.2 Shire (Baxter) Description and Business Overview
6.1.3 Shire (Baxter) Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Shire (Baxter) Recombinant Antihemophilic Globulin Product Portfolio
6.1.5 Shire (Baxter) Recent Developments/Updates
6.2 Bayer Healthcare
6.2.1 Bayer Healthcare Company Information
6.2.2 Bayer Healthcare Description and Business Overview
6.2.3 Bayer Healthcare Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Bayer Healthcare Recombinant Antihemophilic Globulin Product Portfolio
6.2.5 Bayer Healthcare Recent Developments/Updates
6.3 CSL
6.3.1 CSL Company Information
6.3.2 CSL Description and Business Overview
6.3.3 CSL Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 CSL Recombinant Antihemophilic Globulin Product Portfolio
6.3.5 CSL Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Recombinant Antihemophilic Globulin Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Grifols
6.5.1 Grifols Company Information
6.5.2 Grifols Description and Business Overview
6.5.3 Grifols Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Grifols Recombinant Antihemophilic Globulin Product Portfolio
6.5.5 Grifols Recent Developments/Updates
6.6 Biogen
6.6.1 Biogen Company Information
6.6.2 Biogen Description and Business Overview
6.6.3 Biogen Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Biogen Recombinant Antihemophilic Globulin Product Portfolio
6.6.5 Biogen Recent Developments/Updates
6.7 Octapharma
6.7.1 Octapharma Company Information
6.7.2 Octapharma Description and Business Overview
6.7.3 Octapharma Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Octapharma Recombinant Antihemophilic Globulin Product Portfolio
6.7.5 Octapharma Recent Developments/Updates
6.8 Novo Nordisk
6.8.1 Novo Nordisk Company Information
6.8.2 Novo Nordisk Description and Business Overview
6.8.3 Novo Nordisk Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Novo Nordisk Recombinant Antihemophilic Globulin Product Portfolio
6.8.5 Novo Nordisk Recent Developments/Updates
6.9 Greencross
6.9.1 Greencross Company Information
6.9.2 Greencross Description and Business Overview
6.9.3 Greencross Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Greencross Recombinant Antihemophilic Globulin Product Portfolio
6.9.5 Greencross Recent Developments/Updates
6.10 Kedrion
6.10.1 Kedrion Company Information
6.10.2 Kedrion Description and Business Overview
6.10.3 Kedrion Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Kedrion Recombinant Antihemophilic Globulin Product Portfolio
6.10.5 Kedrion Recent Developments/Updates
6.11 BPL
6.11.1 BPL Company Information
6.11.2 BPL Description and Business Overview
6.11.3 BPL Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.11.4 BPL Recombinant Antihemophilic Globulin Product Portfolio
6.11.5 BPL Recent Developments/Updates
6.12 Hualan Bio
6.12.1 Hualan Bio Company Information
6.12.2 Hualan Bio Description and Business Overview
6.12.3 Hualan Bio Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Hualan Bio Recombinant Antihemophilic Globulin Product Portfolio
6.12.5 Hualan Bio Recent Developments/Updates
6.13 RAAS
6.13.1 RAAS Company Information
6.13.2 RAAS Description and Business Overview
6.13.3 RAAS Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.13.4 RAAS Recombinant Antihemophilic Globulin Product Portfolio
6.13.5 RAAS Recent Developments/Updates
6.14 Baxalta
6.14.1 Baxalta Company Information
6.14.2 Baxalta Description and Business Overview
6.14.3 Baxalta Recombinant Antihemophilic Globulin Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Baxalta Recombinant Antihemophilic Globulin Product Portfolio
6.14.5 Baxalta Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Recombinant Antihemophilic Globulin Industry Chain Analysis
7.2 Recombinant Antihemophilic Globulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Recombinant Antihemophilic Globulin Production Mode & Process Analysis
7.4 Recombinant Antihemophilic Globulin Sales and Marketing
7.4.1 Recombinant Antihemophilic Globulin Sales Channels
7.4.2 Recombinant Antihemophilic Globulin Distributors
7.5 Recombinant Antihemophilic Globulin Customer Analysis
8 Recombinant Antihemophilic Globulin Market Dynamics
8.1 Recombinant Antihemophilic Globulin Industry Trends
8.2 Recombinant Antihemophilic Globulin Market Drivers
8.3 Recombinant Antihemophilic Globulin Market Challenges
8.4 Recombinant Antihemophilic Globulin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Shire (Baxter)
Bayer HealthCare
CSL Limited
Pfizer Inc
Grifols S A
Biogen
Octapharma AG
Novo Nordisk
Greencross
Kedrion S p A
BPL
Hualan Bio
RAAS
Baxalta
List of Tables
 Table 1. Global Recombinant Antihemophilic Globulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Recombinant Antihemophilic Globulin Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Recombinant Antihemophilic Globulin Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Recombinant Antihemophilic Globulin Sales (Units) of Key Manufacturers (2020-2025)
 Table 5. Global Recombinant Antihemophilic Globulin Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Recombinant Antihemophilic Globulin Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Recombinant Antihemophilic Globulin Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Recombinant Antihemophilic Globulin Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Recombinant Antihemophilic Globulin, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Recombinant Antihemophilic Globulin, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Recombinant Antihemophilic Globulin, Product Type & Application
 Table 12. Global Key Manufacturers of Recombinant Antihemophilic Globulin, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Recombinant Antihemophilic Globulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Antihemophilic Globulin as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Recombinant Antihemophilic Globulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Recombinant Antihemophilic Globulin Sales by Region (2020-2025) & (Units)
 Table 18. Global Recombinant Antihemophilic Globulin Sales Market Share by Region (2020-2025)
 Table 19. Global Recombinant Antihemophilic Globulin Sales by Region (2026-2031) & (Units)
 Table 20. Global Recombinant Antihemophilic Globulin Sales Market Share by Region (2026-2031)
 Table 21. Global Recombinant Antihemophilic Globulin Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Recombinant Antihemophilic Globulin Revenue Market Share by Region (2020-2025)
 Table 23. Global Recombinant Antihemophilic Globulin Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Recombinant Antihemophilic Globulin Revenue Market Share by Region (2026-2031)
 Table 25. North America Recombinant Antihemophilic Globulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Recombinant Antihemophilic Globulin Sales by Country (2020-2025) & (Units)
 Table 27. North America Recombinant Antihemophilic Globulin Sales by Country (2026-2031) & (Units)
 Table 28. North America Recombinant Antihemophilic Globulin Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Recombinant Antihemophilic Globulin Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Recombinant Antihemophilic Globulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Recombinant Antihemophilic Globulin Sales by Country (2020-2025) & (Units)
 Table 32. Europe Recombinant Antihemophilic Globulin Sales by Country (2026-2031) & (Units)
 Table 33. Europe Recombinant Antihemophilic Globulin Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Recombinant Antihemophilic Globulin Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Recombinant Antihemophilic Globulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Recombinant Antihemophilic Globulin Sales by Region (2020-2025) & (Units)
 Table 37. Asia Pacific Recombinant Antihemophilic Globulin Sales by Region (2026-2031) & (Units)
 Table 38. Asia Pacific Recombinant Antihemophilic Globulin Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Recombinant Antihemophilic Globulin Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Recombinant Antihemophilic Globulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Recombinant Antihemophilic Globulin Sales by Country (2020-2025) & (Units)
 Table 42. Latin America Recombinant Antihemophilic Globulin Sales by Country (2026-2031) & (Units)
 Table 43. Latin America Recombinant Antihemophilic Globulin Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Recombinant Antihemophilic Globulin Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Recombinant Antihemophilic Globulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Recombinant Antihemophilic Globulin Sales by Country (2020-2025) & (Units)
 Table 47. Middle East and Africa Recombinant Antihemophilic Globulin Sales by Country (2026-2031) & (Units)
 Table 48. Middle East and Africa Recombinant Antihemophilic Globulin Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Recombinant Antihemophilic Globulin Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Recombinant Antihemophilic Globulin Sales (Units) by Type (2020-2025)
 Table 51. Global Recombinant Antihemophilic Globulin Sales (Units) by Type (2026-2031)
 Table 52. Global Recombinant Antihemophilic Globulin Sales Market Share by Type (2020-2025)
 Table 53. Global Recombinant Antihemophilic Globulin Sales Market Share by Type (2026-2031)
 Table 54. Global Recombinant Antihemophilic Globulin Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Recombinant Antihemophilic Globulin Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Recombinant Antihemophilic Globulin Revenue Market Share by Type (2020-2025)
 Table 57. Global Recombinant Antihemophilic Globulin Revenue Market Share by Type (2026-2031)
 Table 58. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Recombinant Antihemophilic Globulin Sales (Units) by Application (2020-2025)
 Table 61. Global Recombinant Antihemophilic Globulin Sales (Units) by Application (2026-2031)
 Table 62. Global Recombinant Antihemophilic Globulin Sales Market Share by Application (2020-2025)
 Table 63. Global Recombinant Antihemophilic Globulin Sales Market Share by Application (2026-2031)
 Table 64. Global Recombinant Antihemophilic Globulin Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Recombinant Antihemophilic Globulin Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Recombinant Antihemophilic Globulin Revenue Market Share by Application (2020-2025)
 Table 67. Global Recombinant Antihemophilic Globulin Revenue Market Share by Application (2026-2031)
 Table 68. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Application (2026-2031)
 Table 70. Shire (Baxter) Company Information
 Table 71. Shire (Baxter) Description and Business Overview
 Table 72. Shire (Baxter) Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Shire (Baxter) Recombinant Antihemophilic Globulin Product
 Table 74. Shire (Baxter) Recent Developments/Updates
 Table 75. Bayer Healthcare Company Information
 Table 76. Bayer Healthcare Description and Business Overview
 Table 77. Bayer Healthcare Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Bayer Healthcare Recombinant Antihemophilic Globulin Product
 Table 79. Bayer Healthcare Recent Developments/Updates
 Table 80. CSL Company Information
 Table 81. CSL Description and Business Overview
 Table 82. CSL Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. CSL Recombinant Antihemophilic Globulin Product
 Table 84. CSL Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer Recombinant Antihemophilic Globulin Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Grifols Company Information
 Table 91. Grifols Description and Business Overview
 Table 92. Grifols Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Grifols Recombinant Antihemophilic Globulin Product
 Table 94. Grifols Recent Developments/Updates
 Table 95. Biogen Company Information
 Table 96. Biogen Description and Business Overview
 Table 97. Biogen Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Biogen Recombinant Antihemophilic Globulin Product
 Table 99. Biogen Recent Developments/Updates
 Table 100. Octapharma Company Information
 Table 101. Octapharma Description and Business Overview
 Table 102. Octapharma Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Octapharma Recombinant Antihemophilic Globulin Product
 Table 104. Octapharma Recent Developments/Updates
 Table 105. Novo Nordisk Company Information
 Table 106. Novo Nordisk Description and Business Overview
 Table 107. Novo Nordisk Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Novo Nordisk Recombinant Antihemophilic Globulin Product
 Table 109. Novo Nordisk Recent Developments/Updates
 Table 110. Greencross Company Information
 Table 111. Greencross Description and Business Overview
 Table 112. Greencross Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Greencross Recombinant Antihemophilic Globulin Product
 Table 114. Greencross Recent Developments/Updates
 Table 115. Kedrion Company Information
 Table 116. Kedrion Description and Business Overview
 Table 117. Kedrion Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Kedrion Recombinant Antihemophilic Globulin Product
 Table 119. Kedrion Recent Developments/Updates
 Table 120. BPL Company Information
 Table 121. BPL Description and Business Overview
 Table 122. BPL Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. BPL Recombinant Antihemophilic Globulin Product
 Table 124. BPL Recent Developments/Updates
 Table 125. Hualan Bio Company Information
 Table 126. Hualan Bio Description and Business Overview
 Table 127. Hualan Bio Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Hualan Bio Recombinant Antihemophilic Globulin Product
 Table 129. Hualan Bio Recent Developments/Updates
 Table 130. RAAS Company Information
 Table 131. RAAS Description and Business Overview
 Table 132. RAAS Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. RAAS Recombinant Antihemophilic Globulin Product
 Table 134. RAAS Recent Developments/Updates
 Table 135. Baxalta Company Information
 Table 136. Baxalta Description and Business Overview
 Table 137. Baxalta Recombinant Antihemophilic Globulin Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Baxalta Recombinant Antihemophilic Globulin Product
 Table 139. Baxalta Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Recombinant Antihemophilic Globulin Distributors List
 Table 143. Recombinant Antihemophilic Globulin Customers List
 Table 144. Recombinant Antihemophilic Globulin Market Trends
 Table 145. Recombinant Antihemophilic Globulin Market Drivers
 Table 146. Recombinant Antihemophilic Globulin Market Challenges
 Table 147. Recombinant Antihemophilic Globulin Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Recombinant Antihemophilic Globulin
 Figure 2. Global Recombinant Antihemophilic Globulin Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Recombinant Antihemophilic Globulin Market Share by Type: 2024 & 2031
 Figure 4. Baikoc Product Picture
 Figure 5. Afstyla Product Picture
 Figure 6. Altuviiio Product Picture
 Figure 7. Global Recombinant Antihemophilic Globulin Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Recombinant Antihemophilic Globulin Market Share by Application: 2024 & 2031
 Figure 9. Clinical Treatment
 Figure 10. Drug Research
 Figure 11. Others
 Figure 12. Global Recombinant Antihemophilic Globulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Recombinant Antihemophilic Globulin Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Recombinant Antihemophilic Globulin Sales (2020-2031) & (Units)
 Figure 15. Global Recombinant Antihemophilic Globulin Average Price (US$/Unit) & (2020-2031)
 Figure 16. Recombinant Antihemophilic Globulin Report Years Considered
 Figure 17. Recombinant Antihemophilic Globulin Sales Share by Manufacturers in 2024
 Figure 18. Global Recombinant Antihemophilic Globulin Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Recombinant Antihemophilic Globulin Players: Market Share by Revenue in Recombinant Antihemophilic Globulin in 2024
 Figure 20. Recombinant Antihemophilic Globulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Recombinant Antihemophilic Globulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Recombinant Antihemophilic Globulin Sales Market Share by Country (2020-2031)
 Figure 23. North America Recombinant Antihemophilic Globulin Revenue Market Share by Country (2020-2031)
 Figure 24. United States Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Recombinant Antihemophilic Globulin Sales Market Share by Country (2020-2031)
 Figure 27. Europe Recombinant Antihemophilic Globulin Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Recombinant Antihemophilic Globulin Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Recombinant Antihemophilic Globulin Revenue Market Share by Region (2020-2031)
 Figure 35. China Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Southeast Asia Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Latin America Recombinant Antihemophilic Globulin Sales Market Share by Country (2020-2031)
 Figure 43. Latin America Recombinant Antihemophilic Globulin Revenue Market Share by Country (2020-2031)
 Figure 44. Mexico Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Brazil Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Argentina Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Middle East and Africa Recombinant Antihemophilic Globulin Sales Market Share by Country (2020-2031)
 Figure 48. Middle East and Africa Recombinant Antihemophilic Globulin Revenue Market Share by Country (2020-2031)
 Figure 49. Turkey Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Saudi Arabia Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. UAE Recombinant Antihemophilic Globulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Global Sales Market Share of Recombinant Antihemophilic Globulin by Type (2020-2031)
 Figure 53. Global Revenue Market Share of Recombinant Antihemophilic Globulin by Type (2020-2031)
 Figure 54. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Type (2020-2031)
 Figure 55. Global Sales Market Share of Recombinant Antihemophilic Globulin by Application (2020-2031)
 Figure 56. Global Revenue Market Share of Recombinant Antihemophilic Globulin by Application (2020-2031)
 Figure 57. Global Recombinant Antihemophilic Globulin Price (US$/Unit) by Application (2020-2031)
 Figure 58. Recombinant Antihemophilic Globulin Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Recombinant Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor Recombinant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Antihemophilic Factor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Global Hemophilia monoclonal antibody Market Research Report 2024
Hemophilia Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemophilia Medication Market Research Report 2024
Cryoprecipitated Antihemophilic Factor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Hemophilia AAV Gene Therapy Market Research Report 2024
Global Human Coagulation Factor VIII Market Research Report 2020
Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Haemophilia Treatment Market Insights Forecast to 2030
Global Recombinant Activated Coagulation Factor VII Market Research Report 2025
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Acquired Hemophilia Treatment Market Insights Forecast to 2030
Factor VIII Deficiency Treatment Market
Global Rh Immunoglobulin Market Research Report 2024
Global Recombinant Human Thrombin Protein Market Research Report 2024
Global Recombinant Human Coagulation Factor VIII for Injection Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions